Last edition
News about "DPP1 Inhibitor for COPD"
Boehringer Ingelheim Starts Phase 3 COPD Trial of Verducatib
Boehringer Ingelheim has launched phase 3 AIRWARD trial to assess verducatib’s safety and efficacy in adults with symptomatic COPD.
DPP1 Inhibitor For COPD | 02/11/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members